ATE552859T1 - Pharmazeutische formulierungen zur kontinuierlichen abgabe von peptiden - Google Patents

Pharmazeutische formulierungen zur kontinuierlichen abgabe von peptiden

Info

Publication number
ATE552859T1
ATE552859T1 AT01968868T AT01968868T ATE552859T1 AT E552859 T1 ATE552859 T1 AT E552859T1 AT 01968868 T AT01968868 T AT 01968868T AT 01968868 T AT01968868 T AT 01968868T AT E552859 T1 ATE552859 T1 AT E552859T1
Authority
AT
Austria
Prior art keywords
complexes
peptide
peptides
pharmaceutical formulations
continuous delivery
Prior art date
Application number
AT01968868T
Other languages
English (en)
Inventor
Malcolm Gefter
Original Assignee
Praecis Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praecis Pharm Inc filed Critical Praecis Pharm Inc
Application granted granted Critical
Publication of ATE552859T1 publication Critical patent/ATE552859T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT01968868T 2000-09-13 2001-09-13 Pharmazeutische formulierungen zur kontinuierlichen abgabe von peptiden ATE552859T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23218800P 2000-09-13 2000-09-13
PCT/US2001/028691 WO2002022154A2 (en) 2000-09-13 2001-09-13 Pharmaceutical compositions for sustained drug delivery

Publications (1)

Publication Number Publication Date
ATE552859T1 true ATE552859T1 (de) 2012-04-15

Family

ID=22872187

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01968868T ATE552859T1 (de) 2000-09-13 2001-09-13 Pharmazeutische formulierungen zur kontinuierlichen abgabe von peptiden

Country Status (8)

Country Link
US (2) US7037889B2 (de)
EP (1) EP1320387B1 (de)
JP (1) JP2004508411A (de)
AT (1) ATE552859T1 (de)
AU (1) AU2001289079A1 (de)
DK (1) DK1320387T3 (de)
ES (1) ES2387537T3 (de)
WO (1) WO2002022154A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
WO2002022154A2 (en) * 2000-09-13 2002-03-21 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
AU2003226349B2 (en) * 2002-04-11 2008-01-31 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
EP1494662B1 (de) * 2002-04-11 2012-11-28 Children's Medical Center Corporation Tnp-470-hpma-methacrylsäure kopolymer-konjugate und ihre verwendung
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7314859B2 (en) 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
JP2006523609A (ja) * 2002-12-31 2006-10-19 アルタス ファーマシューティカルズ インコーポレイテッド タンパク質結晶およびイオン性ポリマーの複合体
RU2357750C2 (ru) 2002-12-31 2009-06-10 Элтус Фармасьютикалз Инк. Кристаллы человеческого гормона роста и способы их получения
US20040224024A1 (en) * 2003-04-23 2004-11-11 Massachusetts Institute Of Technology Controlled drug release formulations containing polyion complexes
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
JP2007525507A (ja) * 2004-02-26 2007-09-06 ザ ペン ステイト リサーチ ファンデーション オピオイド増殖因子レセプターを用いる、新生物の処置のための組み合わせ療法
CA2557814A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
WO2007021970A2 (en) * 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Stable pharmaceutical formulations and methods of use thereof
US20090023629A1 (en) * 2005-12-23 2009-01-22 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
US7640223B2 (en) * 2006-11-16 2009-12-29 University Of Tennessee Research Foundation Method of organizing and presenting data in a table using stutter peak rule
JP5305371B2 (ja) * 2007-07-19 2013-10-02 国立大学法人 岡山大学 生物膜透過性組成物及び薬剤の生物膜透過性増強方法
US8524669B2 (en) 2008-10-17 2013-09-03 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
US8759322B2 (en) 2008-11-05 2014-06-24 National University Corporation Tokyo Medical And Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
AU2010253834B2 (en) * 2009-05-27 2013-12-19 Dana-Farber Cancer Institute, Inc. Inhibition 0f inflammation using antagonists of MUC1
WO2011100688A1 (en) 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Improved antagonists of muc1
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
WO2014038641A1 (ja) 2012-09-05 2014-03-13 中外製薬株式会社 アミノ酸およびステリル基が導入されたヒアルロン酸誘導体
US11512147B2 (en) 2017-11-15 2022-11-29 Chugai Seiyaku Kabushiki Kaisha Hyaluronic acid derivative modified with polyethylene glycol

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1053581A (en) 1972-09-15 1979-05-01 Carlos M. Samour Sustained release compositions
CA1188988A (en) 1981-07-02 1985-06-18 Alan G. Walton Chondroitin drug complexes
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US4980150A (en) 1989-04-27 1990-12-25 Zetachron, Inc. Chlorhexidine complex
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5888762A (en) 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
CA2095633C (en) * 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP0593956B1 (de) * 1992-10-21 2002-02-13 Dade Behring Inc. Agglutinationstest unter Anwendung eines multivalenten Liganden
US5763422A (en) 1995-01-27 1998-06-09 Board Of Regents, The University Of Texas System Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5972326A (en) 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5830883A (en) 1995-11-06 1998-11-03 Duquesne University Of The Holy Ghost Methods of creating a unique chitosan and employing the same to form complexes with drugs, delivery of the same within a patient and a related dosage form
DE19649645A1 (de) * 1996-11-29 1998-06-04 Hoechst Ag Mehrfach funktionelles Ligandensystem zur zielzellspezifischen Übertragung von Nukleotidsequenzen
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
DE19712718C2 (de) 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
US6043024A (en) * 1997-04-18 2000-03-28 Abbott Laboratories Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
JP2001513987A (ja) 1997-08-22 2001-09-11 ワシントン大学 誘導性制御システムおよびその使用
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6919372B1 (en) 1997-12-26 2005-07-19 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical compositions
WO1999045389A2 (en) * 1998-03-06 1999-09-10 Abbott Lab Ligand screening and design by x-ray crystallography
EP1073763A4 (de) 1998-04-28 2002-08-07 Univ Washington Verfahren zur transduktion von fusionsmolekulen
AU3347900A (en) * 1999-01-23 2000-08-07 Minerva Biotechnologies Corporation Interaction of colloid-immobilized species with species on non-colloidal structures
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
WO2002022154A2 (en) * 2000-09-13 2002-03-21 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
WO2002044184A2 (en) * 2000-11-30 2002-06-06 The Penn State Research Foundation Dna methyl transferase inhibitors

Also Published As

Publication number Publication date
WO2002022154A2 (en) 2002-03-21
US8084419B2 (en) 2011-12-27
JP2004508411A (ja) 2004-03-18
EP1320387B1 (de) 2012-04-11
US20060094662A1 (en) 2006-05-04
US7037889B2 (en) 2006-05-02
EP1320387A2 (de) 2003-06-25
ES2387537T3 (es) 2012-09-25
DK1320387T3 (da) 2012-07-16
WO2002022154A3 (en) 2003-03-13
US20020086829A1 (en) 2002-07-04
AU2001289079A1 (en) 2002-03-26

Similar Documents

Publication Publication Date Title
ATE552859T1 (de) Pharmazeutische formulierungen zur kontinuierlichen abgabe von peptiden
JO1998B1 (en) Pharmaceutical formulas to maintain continuous delivery of the drug
MXPA02011003A (es) Composiciones farmaceuticas estables de ion metalico-lipido, en polvo, para el suministro de farmacos y metodos de uso.
WO2002051390A3 (en) Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
BG105189A (bg) Капсула от две части за пълнене с фармацевтични препарати за прахови инхалатори
ATE274344T1 (de) Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium
MXPA05007158A (es) Formulacion farmaceutica con un agente activo insoluble.
DE60121570D1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
EP1279406A4 (de) Transporters und arzneimittelabgabesysteme die diese verwenden
NZ534919A (en) Bioactive keratin peptides
MY118371A (en) Tetrahydrolipstatin containing compositions
EP2298279A3 (de) Pharmazeutische Zusammensetzungen zur Inhalation
EA200802350A3 (ru) Система доставки лекарств
SE0402345D0 (sv) A metered medication dose
AU7134898A (en) Biodegradable microparticles for the sustained delivery of therapeutic drugs
WO2007022254A3 (en) Pharmaceutical formulations for sustained drug delivery
Mitsiades et al. Proteasome inhibition as a new therapeutic principle in hematological malignancies
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
WO2007061829A3 (en) Pharmaceutical composition
DE60031259D1 (de) Nährstoffe aus sojabohnenprotein
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
AU9124401A (en) Stabilization of solid thyroid drug formulations
CA2273272A1 (en) Immediate release drug delivery forms
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product